TapImmune Licenses HER2/neu Antigen Technology from Mayo Clinic for Incorporation Into a Vaccine to Treat HER2/neu Breast Cancer
FDA Raids Herbal Distributor Over Cancer Remedies
SEATTLE, Wash., April 16, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) has announced that it has signed an Exclusive Agreement with the Mayo Foundation for Education & Research, Rochester, MN, to License a proprietary MHC Class I HER2/neu antigen technology. (Source: Medical News (via PRIMEZONE)) read more..
source:http://www.medworm.com
FDA Raids Herbal Distributor Over Cancer Remedies
Prisonplanet.com April 17, 2012 It's no secret that the FDA is responsible for some of the most vastly detrimental products on the consumer market, but did you know that they are capable of ... read more..
No comments:
Post a Comment